Purpose: The revised prescription drug labeling ... products approved or submitted for approval under an abbreviated new drug application (ANDA) depends on the labeling of the listed drug ...
The Food and Drug Administration (FDA) has accepted a new drug application (NDA) with priority review for the investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib in the ...
The US Food and Drug Administration (FDA)’s recently issued final rule establishing application, labeling, and postmarketing reporting ...
has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous ...
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...